Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 7Prostatic Neoplasms 3Melanoma 3Lung Neoplasms 3Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Hematologic Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pancreatic Neoplasms 1Moderate Hepatic Impairment 1Meningioma 1Healthy Participants 1Glioma 1Esophageal Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Colonic Neoplasms 1Chondrosarcoma 1Carcinosarcoma 1

Interventions

capivasertib 1Dextromethorphan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Healthy Participants × capivasertib × 90 days × Clear all
NCT07241065 2026-04-15

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants

AstraZeneca

Phase 1 Recruiting
42 enrolled

Healthy Participants

Data powered by HemOnc (CC BY 4.0) Colophon âš¡